## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person* Curd John G				2. Issuer Name and Ticker or Trading Symbol THRESHOLD PHARMACEUTICALS INC [THLD]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X Officer (give title below)  President and CMO						
(Last) (First) (Middle) C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BLVD. SUITE 500			3. Date of Earliest Transaction (Month/Day/Year) 09/01/2009							Pro	esident and C	LMO				
(Street) REDWOOD CITY, CA 94063				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City		(State)	(Zip)		7	Γable 1	I - Non	ı-Deri	ivative	Securities	s Acqu	ired, Disp	osed of, or l	Beneficially	Owned	
(Instr. 3) Da		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, i any (Month/Day/Yea		if Co	(Instr. 8)		(A) or (D)	(A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		ollowing	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						(	Code	V	Amou	or (D)	Price				(I) (Instr. 4)	
Common	Stock		09/01/2009				P		5,000 (1)	A	\$ 1.53	70,342			D	
Reminder:	Report on a s	eparate line for	each class of secur	<b>D</b> erivati	ve Secur	ities A	cquire	Perso conta the fo	ons wl ained i orm di sposed	ho respo in this fo splays a of, or Be	rm are curre reficia	e not requently valid	OMB con	formation spond unle trol numbe	ss	1474 (9-02)
1. Title of	2.	3. Transaction	`	<b>2.g.</b> , put	s, calls, v	varrai 5.	its, op			rtible secu rcisable		itle and	8. Price of	9. Number	of 10.	11. Nature
Derivative Security	Conversion or Exercise Price of Derivative Security	ve (Month/Day/Y		te, if Transaction Code Year) (Instr. 8)		Num of Deri Secu Acqu (A) o Disp of (I (Inst			and Expiration Date (Month/Day/Year)		Am Und Sec	ount of derlying urities tr. 3 and		Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form of Derivat Security Direct ( or Indir	hip of Indirect Beneficial Ownershi (Instr. 4)  D)
				Code	Code V	(A)	(D)	Date Exerc	cisable	Expiration Date	n Titl	Amount or Number of Shares				

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Curd John G C/O THRESHOLD PHARMACEUTICALS, INC. 1300 SEAPORT BLVD. SUITE 500 REDWOOD CITY, CA 94063			President and CMO			

#### **Signatures**

John G. Curd by Joel Fernandes, Attorney-In-Fact	09/01/2009	
**Signature of Reporting Person	Date	

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares were purchased pursuant to the Reporting Person's 10b-5(1) Plan dated May 18, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.